Pages that link to "Q80974691"

The following pages link to Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia (Q80974691):

Displaying 11 items.

• Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study (Q34593276) (← links)
• Gene mutations and molecularly targeted therapies in acute myeloid leukemia. (Q34647741) (← links)
• Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic (Q34817365) (← links)
• The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine (Q35128725) (← links)
• N-ras mutation detection by pyrosequencing in adult patients with acute myeloid leukemia at a single institution (Q36821796) (← links)
• Molecular pathogenesis of acute myeloid leukemia: a diverse disease with new perspectives (Q37815040) (← links)
• High-fidelity DNA polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR assay for K-ras mutations (Q38290037) (← links)
• Prognostic Significance of NRAS Gene Mutations in Children with Acute Myelogenous Leukemia (Q40055219) (← links)
• RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group. (Q53384430) (← links)
• Farnesyltransferase inhibitors in myelodysplastic syndrome (Q84122082) (← links)
• Frequency of KRAS mutations in adult Korean patients with acute myeloid leukemia (Q86492904) (← links)